A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

被引：0
|
作者：
Rischin, D. [1 ,2 ]
Fury, M. G. [3 ]
Lowy, I. [3 ]
Stankevich, E. [3 ]
Li, S. [3 ]
Han, H. [3 ]
Porceddu, S. V. [4 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Regeneron Pharmaceut Inc, Clin Sci, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Univ Queensland, Sch Med, Princess Alexandra Hosp, Dept Radiat Oncol, Herston, Qld, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1372TiP
引用
收藏
页码：560 / 560
页数：1
相关论文
共 50 条
  • [31] Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy
    Kozelsky, TF
    Meyers, GE
    Sloan, JA
    Shanahan, TG
    Dick, SJ
    Moore, RL
    Engeler, GP
    Frank, AR
    McKone, TK
    Urias, RE
    Pilepich, MV
    Novotny, PJ
    Martenson, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1669 - 1674
  • [32] Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study
    Sun, Xu-Shan
    Tao, Yungan
    Le Tourneau, Christophe
    Pointreau, Yoann
    Sire, Christian
    Kaminsky, Marie-Christine
    Coutte, Alexandre
    Alfonsi, Marc
    Boisselier, Pierre
    Martin, Laurent
    Miroir, Jessica
    Ramee, Jean-Francois
    Delord, Jean-Pierre
    Clatot, Florian
    Rolland, Frederic
    Villa, Julie
    Magne, Nicolas
    Elicin, Olgun
    Gherga, Elisabeta
    Nguyen, France
    Lafond, Cedrick
    Bera, Guillaume
    Calugaru, Valentin
    Geoffrois, Lionnel
    Chauffert, Bruno
    Zubel, Angela
    Zanna, Claudio
    Brienza, Silvano
    Crompton, Philippa
    Rouits, Elisabeth
    Gollmer, Kathrin
    Szyldergemajn, Sergio
    Bourhis, Jean
    LANCET ONCOLOGY, 2020, 21 (09) : 1173 - 1187
  • [33] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
    Motzer, Robert J.
    Escudier, Bernard
    Oudard, Stephane
    Hutson, Thomas E.
    Porta, Camillo
    Bracarda, Sergio
    Gruenwald, Viktor
    Thompson, John A.
    Figlin, Robert A.
    Hollaender, Norbert
    Urbanowitz, Gladys
    Berg, William J.
    Kay, Andrea
    Lebwohl, David
    Ravaud, Alain
    LANCET, 2008, 372 (9637) : 449 - 456
  • [34] Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
    Wu, Zhenjie
    Wang, Linhui
    Pandolfo, Savio D.
    Autorino, Riccardo
    EUROPEAN UROLOGY, 2023, 83 (03) : 297 - 298
  • [35] Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial
    Liu, Sai Lan
    Mai, Hai-Qiang
    Wen, Dongxiang
    Yang, Jin-Hao
    Guo, Shan-Shan
    Liu, Li-Ting
    Luo, Mei-Juan
    Liang, YuJing
    Sun, Xue-Song
    Li, Xiao-Yun
    Luo, Dong-Hua
    Li, Ji-Bin
    Wang, Pan
    Guo, Ling
    Mo, Hao-Yuan
    Sun, Rui
    Zhao, Chong
    Xu, Rui-Hua
    Tang, Lin-Quan
    Chen, Qiu-Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
    Park, S.
    Sun, J-M
    Choi, Y-L
    Oh, D.
    Kim, H. K.
    Lee, T.
    Chi, S. A.
    Lee, S-H
    Choi, Y. S.
    Jung, S-H
    Ahn, M-J
    Ahn, Y. C.
    Park, K.
    Shim, Y. M.
    ESMO OPEN, 2022, 7 (01)
  • [37] ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-Results and implications for adjuvant clinical trials
    Belldegrun, Arie S.
    Chamie, Karim
    Kloepfer, Pia
    Fall, Barbara
    Bevan, Paul
    Stoerkel, Stephan
    Wilhelm, Olaf
    Pantuck, Allan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (vol 16, pg 522, 2015)
    Eggermont, A. M. M.
    Chiarion-Sileni, V
    Grob, J-J
    LANCET ONCOLOGY, 2016, 17 (06) : E223 - E223
  • [39] Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma
    Schenker, Michael
    Klochikhin, Mikhail
    Kirtbaya, Dmitry
    Mortier, Laurent
    Gschnell, Martin
    Robert, Caroline
    Meyer, Nicolas
    Flatz, Lukas
    Dalle, Stephane
    Beylot-Barry, Marie
    Eigentler, Thomas
    Silverman, Rachel Kloss
    Gumuscu, Burak
    Yuan, Jianda
    Bratland, Aase
    CLINICAL CANCER RESEARCH, 2023, 29 (18)
  • [40] Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
    Motzer, Robert J.
    Russo, Paul
    Gruenwald, Viktor
    Tomita, Yoshihiko
    Zurawski, Bogdan
    Parikh, Omi
    Buti, Sebastiano
    Barthelemy, Philippe
    Goh, Jeffrey C.
    Ye, Dingwei
    Lingua, Alejo
    Lattouf, Jean-Baptiste
    Albiges, Laurence
    George, Saby
    Shuch, Brian
    Sosman, Jeffrey
    Staehler, Michael
    Vazquez Estevez, Sergio
    Simsek, Burcin
    Spiridigliozzi, Julia
    Chudnovsky, Aleksander
    Bex, Axel
    LANCET, 2023, 401 (10379) : 821 - 832
12345